List of Figures

Figure 1: HNC Regions
Figure 2: Symptoms of HNC
Figure 3: Progression of HNSCC and key Genetic Events
Figure 4: Development of Carcinogen-associated, HPV-negative HNSCC
Figure 5: HPV Infection of the Tonsil Crypt and Development of HPV-positive HNSCC
Figure 6: Treatment Options in Locally Advanced SCCHN (SEOM Clinical Guidelines)
Figure 7: Algorithm for Treatment Decision-making for Recurrent and/or Metastatic HNSCC
Figure 8: Proposed Treatment Algorithm in the First-line Setting for Patients With Recurrent and/or Metastatic HNSCC
Figure 9: Proposed Treatment Algorithm in the Second-line Setting for Patients With Recurrent and/or Metastatic HNSCC
Figure 10: Proposed Treatment Algorithm for Recurrent and/or Metastatic HNSCC Patients After Exposure to First-line Immunotherapy +/? Chemotherapy
Figure 11: Total Incident Cases of Head and Neck Cancer (HNC) in the 7MM (2019–2032)
Figure 12: Total Incident Cases of Head and Neck Cancer (HNC) in the United States (2019–2032)
Figure 13: HPV-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019–2032)
Figure 14: Site-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019–2032)
Figure 15: Molecular Alteration-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019–2032)
Figure 16: Stage-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019–2032)
Figure 17: Total Incident Cases of Head and Neck Cancer (HNC) in EU-5 (2019–2032)
Figure 18: HPV-specific Incident Cases of Head and Neck Cancer (HNC) in EU-5 (2019–2032)
Figure 19: Site-specific Incident Cases of Head and Neck Cancer (HNC) in EU-5 (2019–2032)
Figure 20: Molecular Alteration-specific Incident Cases of Head and Neck Cancer (HNC) in EU-5 (2019–2032)
Figure 21: Stage-specific Incident Cases of Head and Neck Cancer (HNC) in EU-5 (2019–2032)
Figure 22: Total Incident Cases of Head and Neck Cancer (HNC) in Japan (2019–2032)
Figure 23: HPV-specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019–2032)
Figure 24: Site-specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019–2032)
Figure 25: Molecular Alteration-specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019–2032)
Figure 26: Stage-specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019–2032)
Figure 27: Kaplan–Meier Curves for OS in Patients with Recurrent Locoregional Disease or Metastatic SCCHN in EXTREME
Figure 28: OS-CheckMate 141
Figure 29: Kaplan–Meier Curve for OS for KEYTRUDA plus
Figure 30: Kaplan–Meier Curve for OS for KEYTRUDA as
Figure 31: Baseline Demographic and Clinical Characteristics and Efficacy
Figure 32: Market Size of Head and Neck Cancer (HNC), USD Millions (2019–2032)
Figure 33: Market Size of Head and Neck Cancer (HNC) by Therapies in the 7MM, USD Millions (2019–2032)
Figure 34: Total Market Size of Head and Neck Cancer (HNC) in the United States, USD Millions (2019–2032)
Figure 35: Market Size of Head and Neck Cancer (HNC) by Therapies in the United States, USD Million (2019–2032)
Figure 36: Market Size of Head and Neck Cancer (HNC) by Therapies (Adjuvant/Neo-adjuvant) in the United States, USD Million (2019–2032)
Figure 37: Market Size of Head and Neck Cancer (HNC) by Therapies (First-line) in the United States, USD Million (2019–2032)
Figure 38: Market Size of Head and Neck Cancer (HNC) by Therapies (Second-line plus) in the United States, in USD Million (2019–2032)
Figure 40: Market Size of Head and Neck Cancer (HNC) by Therapies in EU-5, USD Million (2019–2032)
Figure 41: Market size of Head and Neck Cancer (HNC) by Therapies (Adjuvant/Neo-adjuvant) in EU-5, USD Million (2019–2032)
Figure 42: Market Size of Head and Neck Cancer (HNC) by Therapies (First-line) in EU-5, USD Million (2019–2032)
Figure 43: Market Size of Head and Neck Cancer (HNC) by Therapies (Second-line plus) in EU-5, USD Million (2019–2032)
Figure 44: Total Market Size of Head and Neck Cancer (HNC) in Japan, USD Millions (2019–2032)
Figure 45: Market Size of Head and Neck Cancer (HNC) by Therapies in Japan, USD Million (2019–2032)
Figure 46: Market size of Head and Neck Cancer (HNC) by Therapies (Adjuvant/Neo-adjuvant) in Japan, USD Million (2019–2032)
Figure 47: Market size of Head and Neck Cancer (HNC) by Therapies in Japan (First-line), USD Million (2019–2032)
Figure 48: Market Size of Head and Neck Cancer (HNC) by Therapies (Second-line plus) in Japan, USD Million (2019–2032)
Figure 49: Unmet needs

List of Tables

Table 1: Summary of Head and Neck Cancer (HNC) (2019–2032)
Table 2: Key Events
Table 3: Work-up for Staging and Diagnosis
Table 4: NCCN Treatment Guidelines for HNC
Table 5: Total Incident Cases of Head and Neck Cancer (HNC) in the 7MM (2019–2032)
Table 6: Total Incident Cases of Head and Neck Cancer (HNC) in the United States (2019–2032)
Table 7: HPV-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019–2032)
Table 8: Site-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019–2032)
Table 9: Molecular Alteration-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019–2032)
Table 10: Stage-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019–2032)
Table 11: Total Incident Cases of Head and Neck Cancer (HNC) in the EU-5 (2019–2032)
Table 12: HPV-specific Incident Cases of Head and Neck Cancer (HNC) in the EU-5 (2019–2032)
Table 13: Site-specific Incident Cases of Head and Neck Cancer (HNC) in the EU-5 (2019–2032)
Table 14: Molecular Alteration-specific Incident Cases of Head and Neck Cancer (HNC) in the EU-5 (2019–2032)
Table 15: Stage-specific Incident Cases of Head and Neck Cancer (HNC) in the EU-5 (2019–2032)
Table 16: Total Incident Cases of Head and Neck Cancer (HNC) in Japan (2019–2032)
Table 17: HPV-specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019–2032)
Table 18: Site-specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019–2032)
Table 19: Molecular Alteration-specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019–2032)
Table 20: Stage-specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019–2032)
Table 21: ERBITUX (Cetuximab), Clinical Trial Description, 2022
Table 22: Efficacy Results in Locoregionally Advanced SCCHN in BONNER
Table 23: Efficacy Results in Recurrent Locoregional Disease or Metastatic SCCHN in EXTREME
Table 24: OPDIVO (nivolumab), Clinical Trial Description, 2022
Table 25: OS-CheckMate 141
Table 26: KEYTRUDA (pembrolizumab), Clinical Trial Description, 2022
Table 27: Efficacy Results* for KEYTRUDA Plus Platinum/Fluorouracil in KEYNOTE-048
Table 28: Efficacy Results* for KEYTRUDA as a Single Agent in KEYNOTE-048 (CPS ?1 and CPS ?20)
Table 29: Key cross competition
Table 30: Leukocyte Interleukin (MULTIKINE), Clinical Trial Description, 2022
Table 31: Toripalimab, Clinical Trial Description, 2022
Table 32: Cabozantinib, Clinical Trial Description, 2022
Table 33: Eftilagimod alpha (Efti/IMP321), Clinical Trial Description, 2022
Table 34: LN-145, Clinical Trial Description, 2022
Table 35: Tislelizumab, Clinical Trial Description, 2022
Table 36: Penpulimab/AK105, Clinical Trial Description, 2022
Table 37: Tipifarnib, Clinical Trial Description, 2022
Table 38: XEVINAPANT (Debio 1143), Clinical Trial Description, 2022
Table 39: AN2025 (buparlisib), Clinical Trial Description, 2022
Table 40: LENVIMA (MK-7902/Lenvatinib), Clinical Trial Description, 2022
Table 41: TECENTRIQ (Atezolizumab), Clinical Trial Description, 2022
Table 42: Cyramza (ramucircumab), Clinical Trial Description, 2022
Table 43: Key Market Forecast Assumptions for ERBITUX (cetuximab)
Table 44: Key Market Forecast Assumptions for OPDIVO (nivolumab)
Table 45: Key Market Forecast Assumptions for KEYTRUDA (pembrolizumab)
Table 46: Key Market Forecast Assumptions for leukocyte interleukin (MULTIKINE)
Table 47: Key Market Forecast Assumptions for toripalimab
Table 48: Key Market Forecast Assumptions for cabozantinib
Table 49: Key Market Forecast Assumptions for Eftilagimod alpha (efti/IMP321)
Table 50: Key Market Forecast Assumptions for LN-145
Table 51: Key Market Forecast Assumptions for tislelizumab (BGB-A317)
Table 52: Key Market Forecast Assumptions for penpulimab
Table 53: Key Market Forecast Assumptions for tipifarnib
Table 54: Key Market Forecast Assumptions for Xevinapant (debio 1143)
Table 55: Key Market Forecast Assumptions for AN2025 (buparlisib)
Table 56: Key Market Forecast Assumptions for LENVIMA (MK-7902/lenvatinib)
Table 57: Key Market Forecast Assumptions for TECENTRIQ (atezolizumab)
Table 58: Key Market Forecast Assumptions for CYRAMZA (ramucirumab)
Table 59: Key Market Forecast Assumptions for CYRAMZA (ramucirumab)
Table 60: Seven Major Market Size of Head and Neck Cancer (HNC), USD Million (2019–2032)
Table 61: Market Size of Head and Neck Cancer (HNC) by Therapies in the 7MM, USD Million (2019–2032)
Table 62: Total Market Size of Head and Neck Cancer (HNC) in the United States, USD Millions (2019–2032)
Table 63: Market Size of Head and Neck Cancer (HNC) by Therapies in the United States, USD Million (2019–2032)
Table 64: Market Size of Head and Neck Cancer (HNC) by Therapies (Adjuvant/Neo-adjuvant) in the United States, USD Million (2019–2032)
Table 65: Market Size of Head and Neck Cancer (HNC) by Therapies in the United States (First-line), in USD Million (2019–2032)
Table 66: Market Size of Head and Neck Cancer (HNC) Cancer by Therapies (Second-line plus) in the United States, USD Million (2019–2032)
Table 67: Total Market Size of Head and Neck Cancer (HNC) in EU-5, USD Million (2019–2032)
Table 68: Market Size of Head and Neck Cancer (HNC) by therapies in EU-5, in USD Million (2019–2032)
Table 69: Market size of Head and Neck Cancer (HNC) by therapies (Adjuvant/Neo-adjuvant) in EU-5, USD Million (2019–2032)
Table 70: Market Size of Head and Neck Cancer (HNC) by Therapies (First-line) in EU-5, USD Million (2019–2032)
Table 71: Market Size of Head and Neck Cancer (HNC) by Therapies (Second-line plus) in EU-5, USD Million (2019–2032)
Table 72: Total Market Size of Head and Neck Cancer (HNC) in Japan, USD Millions (2019–2032)
Table 73: Market Size of Head and Neck Cancer (HNC) by Therapies in Japan, USD Million (2019–2032)
Table 74: Market size of Head and Neck Cancer (HNC) by Therapies (Adjuvant/Neo-adjuvant) in Japan, USD Million (2019–2032)
Table 75: Market size of Head and Neck Cancer (HNC) by Therapies in Japan (First-line), USD Million (2019–2032)
Table 76: Market size of Head and Neck Cancer (HNC) by therapies in Japan (Second-line plus), in USD Million (2019–2032)